Milk Thistle Benefits (2026): Graded by Evidence
Informational summary of published research — not medical advice. Milk thistle is not a substitute for prescribed liver-disease or diabetes treatment, and it is not an antidote for mushroom poisoning, which is a medical emergency — see our full evidence breakdown and safety notes before starting it.
Not every claim made about milk thistle carries the same weight. Its best-supported effect is reducing elevated ALT and AST in fatty liver disease — a real, replicated finding across 26 randomized trials. The liver-boosting reputation stops there for the most part: larger, well-designed trials found no benefit in hepatitis C or alcoholic cirrhosis, and a Cochrane review found no confirmed survival benefit at all. The famous mushroom-poisoning survival statistic is real, but it belongs to an intravenous hospital drug, not the capsule on the shelf. Much of the inconsistency traces back to one practical problem: silymarin is poorly absorbed orally, and most labels don't disclose enough to know what dose you're actually getting.
Looking for a tested product? See our best milk thistle ranked by disclosed silymarin and cost →
The best-evidenced benefit: lowering elevated liver enzymes
This is where milk thistle's data is strongest. A 2024 systematic review and meta-analysis of 26 randomized controlled trials in 2,375 people with nonalcoholic fatty liver disease found silymarin significantly reduced ALT (standardized mean difference −12.39) and AST (−10.97), along with total cholesterol, LDL, and a fatty-liver index, and improved hepatic steatosis on liver histology (odds ratio 3.25 for improvement) (Li 2024, PMID: 38579127). Insulin resistance (HOMA-IR) trended down but didn't reach statistical significance. The honest caveat, which the review's own authors state, is that these are enzyme and imaging markers, not confirmed outcomes like disease reversal, and the effect needs confirming in further research. For the full topic-by-topic evidence table, including this study's finer detail, see our does milk thistle work page.
The mushroom-poisoning story: a real drug, not a real supplement claim
The most dramatic number linked to silymarin is genuine, and it's the most misused. Intravenous silibinin, sold as the hospital drug Legalon SIL, has been used in nearly 1,500 documented cases of Amanita mushroom poisoning, with overall mortality under 10% versus more than 20% for older treatments like penicillin — though there are no controlled trials, for ethical reasons, only case series and uncontrolled treatment data (Mengs 2012, PMID: 22352731). That is a purified, high-dose intravenous infusion given in an ICU. An oral milk thistle capsule does not reproduce those blood levels and has never been shown to treat poisoning — if you or someone you know may have eaten a poisonous mushroom, that's an emergency room visit, not a supplement.
Where the liver claim falls apart: hepatitis C and alcoholic liver disease
Two of the conditions milk thistle is most often marketed for turn out to be its weakest evidence. In a 2012 JAMA trial (the SyNCH study), 154 people with chronic hepatitis C who had already failed interferon-based treatment were randomized to placebo or one of two silymarin doses — 420 mg or 700 mg three times daily, both well above the typical ~140 mg three-times-daily supplement dose — for 24 weeks. Only 2 participants per group met the primary liver-enzyme response target, ALT decline did not differ significantly between groups, and there was no difference in hepatitis C viral load (Fried 2012, PMID: 22797645). Higher-than-normal doses, not a lack of trying, and it still didn't beat placebo.
In alcoholic cirrhosis, a 200-patient, double-blind, multicenter trial randomized people to 450 mg/day silymarin or placebo and tracked time to death over two years. Twenty-nine of the 125 patients who completed the two-year follow-up died — 15 on silymarin, 14 on placebo — and the result held regardless of sex, continued drinking, or disease severity: silymarin had no significant effect on survival or disease course (Parés 1998, PMID: 9566830). A Cochrane review pooling 18 trials (1,088 patients) across both alcoholic and hepatitis B/C liver disease reached the same conclusion at the review level: no significant reduction in all-cause mortality (relative risk 0.78). A liver-related mortality benefit did show up when every trial was pooled, but it disappeared — relative risk 0.57, confidence interval crossing no effect — once the analysis was restricted to the minority of trials (28.6%) rated high quality (Rambaldi 2007, PMID: 17943794). Read the specific trials before the pooled headline: the two largest, best-designed studies in these exact conditions both came back null.
Why the results split this way: absorption, and the phosphatidylcholine fix
A likely reason milk thistle's benefits are inconsistent is that plain silymarin is poorly and unevenly absorbed orally. A human pharmacokinetic study comparing a silybin-phosphatidylcholine complex (IdB 1016, marketed as Siliphos or Realsil) against an equivalent dose of plain silymarin found the complex produced substantially higher blood silybin levels at every time point measured, and confirmed that complexation with phosphatidylcholine improves how much crosses the gut lining into circulation (Barzaghi 1990, PMID: 2088770). That's the actual scientific rationale behind "phytosome" or phosphatidylcholine-complex milk thistle products commanding a premium — and a reasonable factor in why some trials of plain silymarin underperform.
Layer inconsistent manufacturing on top of inconsistent absorption. Independent testing of 26 commercial milk thistle supplements from US and Czech markets found large differences in actual silymarin content, often at odds with what the label claimed, plus contamination with mycotoxins and pesticides across every product tested (Fenclova 2019, PMID: 31366891). Between a poorly absorbed active ingredient and a product category where the dose on the label isn't reliable, a trial finding a modest benefit and a bottle failing to reproduce it are not really in tension — see our label-trap breakdown for how to buy around this.
Standardization, drug interactions, and who should be cautious
A quality product is standardized to ~70–80% silymarin, so the practical buying signal is a printed silymarin percentage you can multiply against the extract weight — see our dosage guide for how to run that math. On drug interactions, the concern is smaller than early lab research suggested: a controlled crossover study giving 10 healthy adults silymarin alongside indinavir, an antiretroviral metabolized through the same CYP3A4/P-glycoprotein pathway researchers worried silymarin might block, found no significant change in indinavir blood levels (DiCenzo 2003, PMID: 12885100). That's one drug in a small trial, not a blanket clearance, so it's still worth telling a pharmacist you're taking it. Two cautions do hold up: milk thistle is in the ragweed family (Asteraceae), so people allergic to ragweed, daisies, or chrysanthemums may react to it (NCCIH; MedlinePlus), and because silymarin may modestly lower fasting glucose in people with type 2 diabetes (Voroneanu 2016, PMID: 27340676, rated low-quality evidence), anyone on antidiabetic medication should monitor and check with a clinician before stacking the two.
Milk thistle benefits at a glance
| Claimed benefit | What the trials found | Verdict |
|---|---|---|
| Elevated liver enzymes (NAFLD) | ALT/AST significantly reduced across 26 RCTs / 2,375 patients (Li 2024) | Best-evidenced, real but modest |
| Amanita mushroom poisoning | ~90%+ survival with IV silibinin in nearly 1,500 hospital cases (Mengs 2012) | Real — but an IV drug, not the capsule |
| Hepatitis C | No benefit on ALT or viral load vs. placebo, even at higher-than-typical doses (Fried 2012) | Null in a well-designed trial |
| Alcoholic liver disease / cirrhosis survival | No survival benefit over 2 years (Parés 1998); no confirmed mortality benefit pooled (Rambaldi 2007) | Null in the largest trials |
| Blood sugar (type 2 diabetes) | Fasting glucose and HbA1c reduced across 5 small RCTs (Voroneanu 2016) | Promising, but low-quality evidence |
Verified milk thistle products
If you want a product where the silymarin dose is actually disclosed rather than a big undisclosed seed-weight number, here's how the milk thistle products we track and verify compare.
Frequently asked questions
What is milk thistle's best-evidenced benefit?
Reducing elevated liver enzymes in fatty liver disease. A 2024 meta-analysis of 26 randomized trials in 2,375 people with NAFLD found silymarin significantly reduced ALT and AST, along with total cholesterol, LDL, and a fatty-liver score, and improved liver histology on biopsy. That's a real, replicated effect. It is not the same as reversing liver disease or proving a survival benefit — treat it as an adjunct for the enzyme numbers, not a cure.
Does milk thistle help with hepatitis C or alcoholic liver disease?
The larger, better-designed trials say no. A 2012 JAMA trial gave 154 people with hepatitis C who'd failed interferon treatment doses of silymarin well above the typical supplement dose for 24 weeks, and found no benefit on liver enzymes or viral load versus placebo. A 200-patient trial in alcoholic cirrhosis found silymarin had no effect on survival over two years. A Cochrane review pooling 18 trials in both conditions found no significant reduction in all-cause mortality, and the liver-mortality benefit that showed up when all trials were pooled disappeared once the review restricted to high-quality trials only.
Is the mushroom-poisoning survival statistic about milk thistle real?
The underlying result is real, but it isn't about the supplement you'd buy. Intravenous silibinin (brand name Legalon SIL), given in a hospital, is associated with mortality under 10% in documented Amanita mushroom poisoning cases, versus over 20% with older treatments. That's a purified, high-dose IV drug administered in an ICU, not an oral capsule. An oral supplement doesn't reach those blood levels and isn't an antidote — mushroom poisoning is a medical emergency, not a reason to reach for a bottle on your shelf.
Why do so many claimed milk thistle benefits have such uneven evidence?
Bioavailability is a big part of it. Plain silymarin is poorly and inconsistently absorbed orally — a human pharmacokinetic study found that complexing silybin with phosphatidylcholine produced much higher blood levels than the same silybin dose from plain silymarin, which is the whole rationale for phosphatidylcholine-complex products. On top of that, independent testing of commercial milk thistle supplements found large, inconsistent variation in actual silymarin content against the label. Between inconsistent absorption and inconsistent dosing, it's not surprising that positive results in tightly controlled trials don't always show up in weaker studies or real-world use.
Related guides
- Does Milk Thistle Work? — our full topic-by-topic evidence table
- The Silymarin Label Trap — why "1,000 mg" on the front isn't the dose
- Milk Thistle Dosage Guide — the ~420 mg/day silymarin target, explained
- Best Milk Thistle Supplement — ranked by disclosed silymarin and cost
- All Milk Thistle Guides
Sources
- Li S, et al. "Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis." Ann Hepatol. 2024;29(2):101174. PMID: 38579127
- Mengs U, et al. "Legalon® SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning." Curr Pharm Biotechnol. 2012;13(10):1964-70. PMID: 22352731
- Fried MW, et al. "Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial." JAMA. 2012;308(3):274-82. PMID: 22797645
- Parés A, et al. "Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial." J Hepatol. 1998;28(4):615-21. PMID: 9566830
- Rambaldi A, et al. "Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases." Cochrane Database Syst Rev. 2007;(4):CD003620. PMID: 17943794
- Barzaghi N, et al. "Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects." Eur J Drug Metab Pharmacokinet. 1990;15(4):333-8. PMID: 2088770
- Fenclova M, et al. "Poor chemical and microbiological quality of the commercial milk thistle-based dietary supplements may account for their reported unsatisfactory and non-reproducible clinical outcomes." Sci Rep. 2019;9(1):11118. PMID: 31366891
- DiCenzo R, et al. "Coadministration of milk thistle and indinavir in healthy subjects." Pharmacotherapy. 2003;23(7):866-70. PMID: 12885100
- Voroneanu L, et al. "Silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of RCTs." J Diabetes Res. 2016;2016:5147468. PMID: 27340676
- NCCIH, "Milk Thistle" (nccih.nih.gov) and MedlinePlus, "Milk thistle" (medlineplus.gov) — ragweed/Asteraceae allergy caution. Consumer-health references, not clinical trials.